Pharma Manufacturing’s Post

Biologics CDMO Avid Bioservices announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act with respect to its pending $1.1 billion acquisition by GHO Capital Partners and Ampersand Capital Partners. GHO Capital Partners LLP, Ampersand Capital Partners #AvidBioservices #GHOCapitalPartners #AmpersandCapitalPartners #biologics #CDMO #pharmanews #pharmamanufacturing https://lnkd.in/gauGgf5d

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics